Translate Bio Expands Patent Portfolio With Newly Issued US Patent Relating to its mRNA Therapeutics Platform

Translate Bio recently announced that the USPTO has issued US Patent No. 10,143,758, Liver Specific Delivery of Messenger RNA, which builds on the company’s 2009 patent filing relating to liposomal delivery of therapeutic mRNA to the liver, enhancing the company’s current intellectual property by providing additional coverage for core delivery capabilities. This patent is owned by Translate Bio and provides protection until March, 2032.

“Since the inception of our technology, our scientists have been focused on the design and delivery of mRNA as a therapeutic and on building our intellectual property to support our discoveries,” said Ron Renaud, Chief Executive Officer of Translate Bio. “This patent reflects the early, pioneering work of our scientists to advance the field of mRNA therapeutics with the goal of delivering innovative treatments to patients suffering from debilitating genetic diseases.”

This newly granted patent is part of an expanding and comprehensive portfolio of patent applications and other intellectual property supporting Translate Bio’s messenger RNA therapeutics (MRT) platform, and particularly its MRT liver delivery system. The company’s intellectual property portfolio is composed of significant patents and patent applications supporting mRNA biology and manufacturing, as well as multiple delivery systems, which the company believes are important for the development and commercialization of a wide range of mRNA therapeutics. In aggregate, Translate Bio owns or has exclusively in-licensed over 300 active patent cases, with over 90 granted or allowed patents worldwide of which over 50 have been granted or allowed in the US or Europe.

Translate Bio’s MRT platform is designed to develop product candidates that deliver mRNA that can carry instructions to produce intracellular, transmembrane, and secreted proteins. The MRT platform is also designed to be flexible and scalable by allowing for the development of MRT product candidates that may vary only in the mRNA coding sequence and/or the tissue-specific delivery system. This modular nature of the MRT platform may allow for rapid advancement into new indications that are amenable to our established delivery systems. Currently, the company is utilizing its MRT platform to identify and rapidly develop new product candidates designed to address the underlying causes of diseases beyond our initial efforts in the lung, to treat cystic fibrosis, and in the liver, to treat OTC deficiency.

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company’s MRT platform is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. Translate Bio believes that its MRT platform and its MRT delivery systems are applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, and lymphatic system. The company also believes its MRT platform and MRT delivery systems may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. Translate Bio’s two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. For more information, visit www.translate.bio.